• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Atopic-like dermatitis after secukinumab injection: A case report.

作者信息

Burlando Martina, Cozzani Emanuele, Russo Roberto, Parodi Aurora

机构信息

Department of Dermatology, Policlinico San Martino- IRCSS, Genoa, Italy.

出版信息

Dermatol Ther. 2019 Jan;32(1):e12751. doi: 10.1111/dth.12751. Epub 2018 Nov 11.

DOI:10.1111/dth.12751
PMID:30238583
Abstract
摘要

相似文献

1
Atopic-like dermatitis after secukinumab injection: A case report.司库奇尤单抗注射后出现类特应性皮炎：一例报告。
Dermatol Ther. 2019 Jan;32(1):e12751. doi: 10.1111/dth.12751. Epub 2018 Nov 11.
2
Remittive effect of Dupilumab in atopic dermatitis.度普利尤单抗在特应性皮炎中的缓解作用。
Dermatol Ther. 2018 Nov;31(6):e12711. doi: 10.1111/dth.12711. Epub 2018 Sep 25.
3
Eyelid Dermatitis as a Side Effect of Interleukin-17A Inhibitors in Psoriasis.眼睑皮炎作为银屑病中白细胞介素-17A抑制剂的一种副作用
Acta Derm Venereol. 2018 Apr 16;98(4):456-457. doi: 10.2340/00015555-2871.
4
Two cases of atopic dermatitis-like conditions induced in psoriasis patients treated with infliximab.
J Eur Acad Dermatol Venereol. 2007 Oct;21(9):1272-4. doi: 10.1111/j.1468-3083.2007.02165.x.
5
Anti IL-17 flared psoriasis in a patient on secukinumab.一名接受司库奇尤单抗治疗的患者出现抗白细胞介素-17诱发的银屑病。
Dermatol Ther. 2017 Jul;30(4). doi: 10.1111/dth.12505. Epub 2017 May 26.
6
Inadequate response to ustekinumab in atopic dermatitis - a report of two patients.乌司奴单抗治疗特应性皮炎疗效不佳——两例患者报告
J Eur Acad Dermatol Venereol. 2016 Mar;30(3):522-3. doi: 10.1111/jdv.12918. Epub 2014 Dec 16.
7
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).预充式注射器给药司库奇尤单抗治疗银屑病的疗效、安全性和使用结果：一项随机对照试验（FEATURE）。
Br J Dermatol. 2015 Feb;172(2):484-93. doi: 10.1111/bjd.13348. Epub 2014 Dec 11.
8
Perioral dermatitis.口周皮炎
Lancet. 1980 Jan 12;1(8159):75-6.
9
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).司库奇尤单抗注射液/笔治疗银屑病的疗效、安全性和实用性：一项随机对照试验（JUNCTURE）。
J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90. doi: 10.1111/jdv.12751. Epub 2014 Sep 22.
10
Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.司库奇尤单抗治疗中重度银屑病长达 3 年，疗效持续良好且安全性良好：一项双盲扩展研究的结果。
Br J Dermatol. 2017 Oct;177(4):1033-1042. doi: 10.1111/bjd.15706. Epub 2017 Sep 4.

引用本文的文献

1
Treatment of Secukinumab-induced Atopic Dermatitis-like Lesions Using Upadacitinib: A Case Report.使用乌帕替尼治疗司库奇尤单抗诱导的特应性皮炎样皮损：一例报告
Indian J Dermatol. 2025 Sep-Oct;70(5):292-294. doi: 10.4103/ijd.ijd_446_24. Epub 2025 Sep 1.
2
Successful Treatment of Ixekizumab-Induced Paradoxical Eczematous Reaction with JAK Inhibitors: A Case Report.使用JAK抑制剂成功治疗司库奇尤单抗诱导的矛盾性湿疹反应：一例报告
Clin Cosmet Investig Dermatol. 2025 Sep 2;18:2133-2139. doi: 10.2147/CCID.S541725. eCollection 2025.
3
Case report: Eczematous adverse drug reaction after selpercatinib treatment.
病例报告：塞尔帕替尼治疗后出现的湿疹样药物不良反应。
Front Oncol. 2024 Dec 24;14:1475541. doi: 10.3389/fonc.2024.1475541. eCollection 2024.
4
Application of JAK inhibitors in paradoxical reaction through immune-related dermatoses.JAK 抑制剂在免疫相关性皮肤病致反常反应中的应用。
Front Immunol. 2024 Feb 20;15:1341632. doi: 10.3389/fimmu.2024.1341632. eCollection 2024.
5
Prurigo Nodularis onset during secukinumab treatment of psoriasis: a case report.司库奇尤单抗治疗银屑病期间发生结节性痒疹：一例报告
Allergy Asthma Clin Immunol. 2023 Jul 5;19(1):59. doi: 10.1186/s13223-023-00811-5.
6
A Review of the Safety of Interleukin-17A Inhibitor Secukinumab.白细胞介素-17A抑制剂司库奇尤单抗的安全性综述
Pharmaceuticals (Basel). 2022 Nov 7;15(11):1365. doi: 10.3390/ph15111365.
7
Eczematous eruption after brodalumab successfully treated with guselkumab and dupilumab.布罗达单抗治疗成功后出现湿疹样皮疹，使用古塞库单抗和度普利尤单抗治疗。
Dermatol Ther. 2022 Nov;35(11):e15839. doi: 10.1111/dth.15839. Epub 2022 Sep 23.
8
Pathogenesis of Paradoxical Reactions Associated with Targeted Biologic Agents for Inflammatory Skin Diseases.与用于炎症性皮肤病的靶向生物制剂相关的反常反应的发病机制。
Biomedicines. 2022 Jun 23;10(7):1485. doi: 10.3390/biomedicines10071485.
9
Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System.司库奇尤单抗的上市后安全性问题：对美国食品药品监督管理局不良事件报告系统的不成比例性分析
Front Pharmacol. 2022 Jun 8;13:862508. doi: 10.3389/fphar.2022.862508. eCollection 2022.
10
Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis.特应性皮炎作为司库奇尤单抗治疗银屑病的矛盾效应
Case Rep Dermatol. 2021 Jul 9;13(2):336-339. doi: 10.1159/000513467. eCollection 2021 May-Aug.